AI tumor board review for prostate cancer
Prostate cancer often has more than one reasonable path, and each specialty weighs them differently. A tumor board exists to put those views side by side before anyone commits.
Where the specialties split
Where the specialties at a prostate cancer tumor board split
- Biochemical recurrence after prostatectomy
- When PSA rises after surgery, the board weighs salvage radiation to the prostate bed, with or without the pelvic lymph nodes and hormone therapy, and how soon to start.
- PSMA PET-detected recurrence
- PSMA PET can find disease that conventional imaging misses. Radiology and nuclear medicine weigh how certain each finding is; radiation oncology and urology weigh whether to treat it directly.
- Low- or high-volume metastatic hormone-sensitive disease (mHSPC)
- How much metastatic disease there is shapes how far systemic therapy goes beyond hormone therapy alone, and whether radiation to the prostate adds anything.
- Localized disease
- Urology and radiation oncology can weigh surgery and radiation differently, and both against active surveillance when the disease is lower risk.
Who sits at the board
Who sits at a prostate cancer tumor board
- Urology
- Radical prostatectomy, active surveillance, and the course of PSA after surgery.
- Medical oncology
- Hormone therapy, and the systemic therapy added to it in advanced disease.
- Radiation oncology
- Curative, salvage and metastasis-directed radiation.
- Pathology
- Grade Group and what the surgical specimen shows, such as the margins and the lymph nodes.
- Radiology
- MRI, CT and bone imaging, and how far each finding can be trusted.
- Nuclear medicine
- PSMA PET findings and how certain each one is.
These are the specialties whose positions appear in the sample report.
Who it is for
For the physicians who treat prostate cancer close to home
- Urologists and oncologists in community practice
- Every discipline’s reasoning on a prostate cancer case, in writing, before the plan is set.
- Practices that refer to academic centers
- The review can travel with the referral, so the receiving team starts from every discipline’s position and the questions still open.
Sample report
A recurrence after prostatectomy, start to finish
The sample report follows a synthetic 70-year-old man whose PSA is rising after radical prostatectomy. PSMA PET shows a recurrence at the resection site and enlarged lymph nodes beside the aorta.
The board sets out the most likely branch, low-volume metastatic hormone-sensitive disease, and holds back a definitive call until testosterone, the timeline of prior therapy and formal staging of any spread are in. Each specialty’s position, and where it disagreed, is in the report.
Clinical deliberation summary · Decision support, not a clinical decision · Research-drafted — not clinician-verified
Delibera · GU Tumor Board · Deliberation Summary
70-year-old Grade Group 2 prostate cancer
Primary recommendation
No definitive call until serum testosterone, prior-therapy timeline, and formal cM adjudication return — then treat as conditional framework below.
Medical Oncologist
Where this specialty disagreed
- Partial agreementwith Radiologist: Agree that imaging shows progression and suspicious para-aortic disease, but disagree with describing this as CHAARTED high-volume disease.
- Dissentwith Nuclear Medicine: The PSMA read is useful, but present-tense RLT eligibility is premature and wrong for the unresolved disease state.
More GU cancers
- The GU tumor board: prostate, bladder and kidney cancer
- Bladder cancer In development.
- Kidney cancer In development.
Request access for your practice
Prostate cancer reviews are available now; bladder and kidney cancer reviews are in development. We read every request and will get back to you within two business days.
Request access